secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2026-08-04T11:08:37+00:00
Accession:  0001104659-26-090056
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio CEO Antony Koblish departs; Heather Getz appointed CEO and director
----------------------------------------------------------------------------

- Antony Koblish ceased as CEO and resigned from board on Aug 3, 2026; no disagreement with company.
- Heather Getz appointed CEO and Class II director effective Aug 3, 2026; 25+ years healthcare experience.
- Employment agreement: $650k base salary, 100% target bonus, severance, and initial equity grants.
- Initial equity grants: 1,365,000 standard options, 1,005,000 premium-priced options, 500,000 RSUs.
- Potential top-up grants if equity financings within 18 months; total could reach 5% of outstanding shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926090056/0001104659-26-090056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926090056/tm2622121d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-090056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer